| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffe2fed8173254afae36a1088e5392f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_635f0e53496f696878f9cdf7eef9c9f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08e518c9469c0d8aed8634dc54203812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ff813a9a6da12f6141512068da2f744
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d841b887276957e9e3975615d4c032e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5400cfbf5c4f6cafc43674e703c35753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_950d9cb38b89cd0e369326eba9774a90 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-18 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-18 |
| filingDate |
1997-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccac5abc6403892aadbe930a975cd3e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2178c082e1911c4b2bce07c3eabc492d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b27ff8aa1c3522bb0671573f92b93c52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbd682bdcfde7282b2bd2fcbd9c2ed0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62937de2a27f9b5676faa2364b20503d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_475f463ddb91750682dc649d6b2e073a |
| publicationDate |
1998-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9807746-A1 |
| titleOfInvention |
B1-bradykinin receptor antagonists and use thereof |
| abstract |
The present invention relates to novel antagonists to a B1-bradykinin (B1-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B1 receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B1-BK receptors in these two models. B1-BK antagonists abolished the vasocontraction induced by B1-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B1-antagonists are useful for treating any condition wherein B1-receptor is expressed, particularly during inflammation, and more particularly wherein B1-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B1-receptor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8278280-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10039846-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2895204-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7605120-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014040192-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006017938-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9920096-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7932228-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7211566-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005042027-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014207534-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8288351-B2 |
| priorityDate |
1996-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |